Hints and tips:
...Allergan could not be reached for comment. Cinven declined to comment....
...The acquisition is the biggest transaction in pharmaceuticals since 2019, when AbbVie acquired Allergan for $63bn, and the largest deal to target a US company in any sector this year....
...taxes by capturing Allergan’s Irish tax incorporation....
...Appaloosa currently holds a 0.35 per cent stake in Allergan, according to Eikon data, making it Allergan’s 44th largest shareholder....
...The Financial Times earlier this month disclosed that JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Allergan on a planned $63bn...
...Shire’s appeal to Allergan is not hard to fathom. Allergan shed its original generics business for $33bn in 2016, in a well-timed deal. Instead, it wants to acquire early-stage drugs....
...Allergan said it had not yet made an offer to Shire....
...Shire on Friday confirmed that Allergan had backed away....
...Allergan briefly entered the fray just hours later, disclosing it was considering a bid but had not yet made an official offer....
...According to Silvana van Schaik, manager for healthcare and chemicals at research provider Sustainalytics, the 2016 outcry persuaded some pharma companies, led by Ireland-headquartered Allergan, to commit...
...The firm’s original investment in Allergan was a money-spinner, reaping gains of $2.3bn before the company agreed a sale to Actavis....
...Allergan of the US considered a counter bid, before ruling itself out for now. Yet mention of Allergan only highlights the contrast between US and UK political interventions....
...A year ago, Brent Saunders, chief executive of drug titan Allergan PLC, enjoyed a reputation as the last pharma boss with a honourable reputation....
...Other large drugmakers, including Allergan, GlaxoSmithKline, Gilead, Shire, Biogen, Teva, Baxter and Viiv also increased the US list prices of their medicines on January 1, according to the data....
...He has since tried to reshape the drugmaker through attempted acquisitions of Anglo-Swedish AstraZeneca and Dublin-based Allergan, although both tie-ups were thwarted by politicians worried about jobs and...
...In August, Teva reported a $6bn loss and slashed its dividend after incurring a $6.1bn impairment charge on its US generics business, which includes the Allergan unit it bought last year for about $40.5bn...
...The relevant SEC filings were made by Allergan, Inc. prior to its acquisition by Actavis plc....
...The company is weathering a rough patch, and recently come under criticism from shareholders for its $40bn acquisition of Allergan’s generic drugs business last year, for which some shareholders and analysts...
...Competitors such as Pfizer, Allergan and Shire have secured intellectual property through acquisition while Mr Soriot has placed a greater emphasis on developing products in house....
...Allergan recently acquired another smaller Nash-focused drugmaker, Arkana, for $50m....
...Allergan may then make additional payments of up to $1.27bn dependent on the success of the drug’s development....
...Depending on whether the drug sells in sufficient quantities, Allergan will pay an additional $725m to AstraZeneca as well as various royalties....
...Since then competitors such as Pfizer, as well as Allergan and Shire have focused on securing promising research by acquiring other companies....
...RBC named as potential bidders the privately owned Purdue Pharmaceuticals, along with listed peers Endo Pharmaceuticals, Allergan and Johnson & Johnson....
International Edition